1034467-80-5

Basic information

• Product Name: 5-cyclopropyl-2-fluoropyridine
• Synonyms: 5-cyclopropyl-2-fluoropyridine;5-Cyclopropyl-2-flluoropyridine
• CAS NO: 1034467-80-5
• Molecular Formula: C₈H₈FN
• Molecular Weight: 137.1542232
• Mol File: 1034467-80-5.mol

Chemical Properties

• Appearance: /
• Storage Temp.: Inert atmosphere,Room Temperature
• CAS DataBase Reference: 5-cyclopropyl-2-fluoropyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 5-cyclopropyl-2-fluoropyridine(1034467-80-5)
• EPA Substance Registry System: 5-cyclopropyl-2-fluoropyridine(1034467-80-5)

Safety Data

• Hazardous Substances Data: 1034467-80-5(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical and Agrochemical Industries:
5-cyclopropyl-2-fluoropyridine is used as a building block in the synthesis of pharmaceuticals and agrochemicals. Its unique properties and structural features make it a valuable intermediate for the development of new drugs and agrochemicals with improved efficacy and selectivity.
Used in Medicinal Chemistry Research:
5-cyclopropyl-2-fluoropyridine is used as a key intermediate in medicinal chemistry research for the design and synthesis of novel compounds with potential therapeutic applications. Its unique structural features allow for the exploration of new chemical space and the development of innovative drug candidates.
Used in Drug Discovery Research:
In drug discovery research, 5-cyclopropyl-2-fluoropyridine is employed as a starting material for the synthesis of diverse chemical libraries. Its unique properties enable the generation of a wide range of structurally diverse compounds, facilitating the identification of new lead compounds with potential therapeutic activity.
Used in Organic Chemistry:
5-cyclopropyl-2-fluoropyridine is utilized as a versatile intermediate in organic chemistry for the synthesis of various organic compounds. Its unique structural features and reactivity make it a valuable building block for the preparation of complex organic molecules and the development of new synthetic methodologies.

Upstream product

• 171197-80-1 2-fluoro-5-iodopyridine 
• 411235-57-9 cyclopropylboronic acid 
• 766-11-0 5-bromo-2-fluoropyridine 

Relevant articles and documents

PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND THEIR USE

The present invention provides, in part, novel small molecule inhibitors of PHD, having a structure according to Formula (A), and sub-formulas thereof: or a pharmaceutically acceptable salt thereof. The compounds provided herein can be useful for treatmen

Anti-tumor activity with acetylene derivatives

The present invention relates to an aromatic ring disubstituted acetylene derivative of formula I, a pharmaceutical composition comprising the compound, and a use of the compound and of the pharmaceutical composition in the treatment and/or prevention of tumors, where A, B, T, M, Ra, Rb, Rt, m, n, and p are as defined in the present document.

PYRAZOLE DERIVATIVES AS DIHYDROOROTATE DEHYDROGENASE (DHODH) INHIBITORS

The present invention relates to compounds of formula (I) for their use in the treatment and/or prevention of auto-immune or auto-immune related diseases, cancer, viral infections, and central nervous system diseases and disorders, by inhibiting human deh

Original 2-(3-Alkoxy-1 H -pyrazol-1-yl)azines Inhibitors of Human Dihydroorotate Dehydrogenase (DHODH)

Following our discovery of human dihydroorotate dehydrogenase (DHODH) inhibition by 2-(3-alkoxy-1H-pyrazol-1-yl)pyrimidine derivatives as well as 2-(4-benzyl-3-ethoxy-5-methyl-1H-pyrazol-1-yl)-5-methylpyridine, we describe here the syntheses and evaluation of an array of azine-bearing analogues. As in our previous report, the structure-activity study of this series of human DHODH inhibitors was based on a phenotypic assay measuring measles virus replication. Among other inhibitors, this round of syntheses and biological evaluation iteration led to the highly active 5-cyclopropyl-2-(4-(2,6-difluorophenoxy)-3-isopropoxy-5-methyl-1H-pyrazol-1-yl)-3-fluoropyridine. Inhibition of DHODH by this compound was confirmed in an array of in vitro assays, including enzymatic tests and cell-based assays for viral replication and cellular growth. This molecule was found to be more active than the known inhibitors of DHODH, brequinar and teriflunomide, thus opening perspectives for its use as a tool or for the design of an original series of immunosuppressive agent. Moreover, because other series of inhibitors of human DHODH have been found to also affect Plasmodium falciparum DHODH, all the compounds were assayed for their effect on P. falciparum growth. However, the modest in vitro inhibition solely observed for two compounds did not correlate with their inhibition of P. falciparum DHODH.

IMIDAZOLIDINONYL AMINOPYRIMIDINE COMPOUNDS FOR THE TREATMENT OF CANCER

The present invention provides novel imidazolidinonyl aminopyrimidine compounds believed to have clinical use for treatment of cancer through inhibiting Plk1. Formula I wherein: R1 is aminomethyl, (C1-C3 alkyl)aminomethyl, di(C1-C2 alkyl)aminomethyl, N- ethyl-N-methyl-aminomethyl, 1-aminoethyl, 1-((C1-C2 alkyl)amino)-ethyl, 3,3,3- trifluoropropylaminomethyl, ethynyl, 2-hydroxy-ethoxy, 2-hydroxyethylaminomethyl, 2- cyanoethylaminomethyl, mopholin-4-ylmethyl, methoxymethoxymethyl, cyclopropyl, 1- azetidinylmethyl, 1-pyrrolidinylmethyl, or 1,3-dioxolan-2-yl; R2 is hydrogen or halo; R3 is hydrogen or halo; provided that at least one of R2 and R3 is hydrogen; R4 is hydrogen, methyl, or halo; and is a single bond that is either present or absent, or a pharmaceutically acceptable salt thereof.

TRIAZOLYL AMINOPYRIMIDINE COMPOUNDS

The present invention provides triazolyl aminopyrimidine compounds useful in the treatment of cancer.